Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance.

No abstract is available for this paper.

• Publication year

  2019

• Venue

  American Journal of Cancer Research

• Publication date

  2019-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 31218111PMCID PMC6556597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies

  2018cited by this paper
• How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies

  2018cited by this paper
• MCL-1 is a prognostic indicator and drug target in breast cancer

  2018cited by this paper
• Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling.

  2018cited by this paper
• Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation

  2018cited by this paper
• Cross-talk between protein synthesis, energy metabolism and autophagy in cancer.

  2018cited by this paper
• Alarming Burden of Triple‐Negative Breast Cancer in India

  2017cited by this paper
• Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells

  2017cited by this paper
• Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

  2017cited by this paper
• Mcl-1 inhibitors: a patent review

  2017cited by this paper
• Anti‐EGFR monoclonal antibodies enhance sensitivity to DNA‐damaging agents in BRCA1‐mutated and PTEN‐wild‐type triple‐negative breast cancer cells

  2017cited by this paper
• PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells

  2017cited by this paper
• MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

  2017cited by this paper
• Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development

  2017cited by this paper
• Attacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL‐2 family members

  2016cited by this paper
• The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

  2016cited by this paper
• Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

  2016cited by this paper
• Targeting the translation machinery in cancer

  2015cited by this paper
• Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells

  2015cited by this paper
• Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer

  2015cited by this paper
• Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

  2015cited by this paper
• Control of cell migration through mRNA localization and local translation

  2015cited by this paper
• Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.

  2014cited by this paper
• Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

  2014cited by this paper
• Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia

  2014cited by this paper
• Homoharringtonine and omacetaxine for myeloid hematological malignancies

  2014cited by this paper
• U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.

  2014cited by this paper
• Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis

  2013cited by this paper
• Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

  2012cited by this paper
• Investigation into omacetaxine solution stability for in vitro study.

  2012cited by this paper
• Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation*

  2012cited by this paper
• Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

  2011cited by this paper
• The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy

  2011cited by this paper
• Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.

  2009cited by this paper
• Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Unique biology of Mcl-1: therapeutic opportunities in cancer.

  2008cited by this paper
• A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

  2006cited by this paper
• Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro‐apoptotic bax and inducing caspase‐3‐mediated cleavage of poly(ADP‐ribose) polymerase (PARP)

  2004cited by this paper
• [Induction of apoptosis by harringtonine and homoharringtonine in HL-60 cells].

  1994cited by this paper
• Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma.

  1990cited by this paper
• Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation

  1989cited by this paper
• A clinical trial of homoharringtonine in the treatment of advanced breast cancer.

  1986cited by this paper
• Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas.

  1986cited by this paper
• A clinical trial of homoharringtonine in the treatment of advanced breast cancer.

  1986cited by this paper
• c-myc oncogene protein synthesis is independent of the cell cycle in human and avian cells

  1985cited by this paper

• Cancer chemoprevention: signaling pathways and strategic approaches

  2025cites this paper
• HSF1 Activation Mechanisms, Disease Roles, and Small Molecule Therapeutics

  2025cites this paper
• Homoharringtonine: mechanisms, clinical applications and research progress

  2025cites this paper
• Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer

  2025cites this paper
• Mitochondrial-targeting strategies with homoharringtonine: A novel approach for chemoresistant rectal cancer.

  2024cites this paper
• Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma

  2024cites this paper
• Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications

  2024cites this paper
• Homoharringtonine as a PHGDH inhibitor: Unraveling metabolic dependencies and developing a potent therapeutic strategy for high-risk neuroblastoma.

  2023cites this paper
• XMR: an explainable multimodal neural network for drug response prediction

  2023cites this paper
• Understanding the Artemia Salina (Brine Shrimp) Test: Pharmacological Significance and Global Impact.

  2023cites this paper
• NKD1 targeting PCM1 regulates the therapeutic sensitivity of HHT on colorectal cancer cells

  2023cites this paper
• NKD1 targeting PCM1 regulates the therapeutic effects of homoharringtonine on colorectal cancer

  2023cites this paper
• Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer

  2023cites this paper
• The Marine Natural Compound Dragmacidin D Selectively Induces Apoptosis in Triple-Negative Breast Cancer Spheroids

  2023cites this paper
• Ginsenoside Rd Induces Differentiation of Myeloid Leukemia Cells via Regulating ERK/GSK-3β Signaling Pathway

  2023cites this paper
• Homoharringtonine induces apoptosis of mammary carcinoma cells by inhibiting the AKT/mTOR signaling pathway.

  2023cites this paper
• Phytochemicals for mitigating the COVID-19 crisis: evidence from pre-clinical and clinical studies

  2023cites this paper
• The Molecular Circadian Clock Is a Target of Anti-cancer Translation Inhibitors

  2023cites this paper
• Enantioselective semisynthesis of novel cephalotaxine esters with potent antineoplastic activities against leukemia.

  2022cites this paper
• Modern Approaches in the Discovery and Development of Plant-Based Natural Products and Their Analogues as Potential Therapeutic Agents

  2022cites this paper
• Differences in potential key genes and pathways between primary and radiation-associated angiosarcoma of the breast

  2022cites this paper
• Nonsense-mediated RNA decay: an emerging modulator of malignancy

  2022cites this paper
• Identification and Quantification of Flavonoids in Okra (Abelmoschus esculentus L. Moench) and Antiproliferative Activity In Vitro of Four Main Components Identified

  2022cites this paper
• Function and Regulation of the Calcium-Activated Chloride Channel Anoctamin 1 (TMEM16A).

  2022cites this paper
• Identification of Homoharringtonine as a potent inhibitor of glioblastoma cell proliferation and migration.

  2022cites this paper
• Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel

  2022cites this paper
• Krüppel-like factor 7 influences translation and pathways involved in ribosomal biogenesis in breast cancer

  2022cites this paper
• Ribosome biogenesis and ribosome therapy in cancer cells

  2022cites this paper
• Identifying Hub Genes Associated with Neoadjuvant Chemotherapy Resistance in Breast Cancer and Potential Drug Repurposing for the Development of Precision Medicine

  2022cites this paper
• Phytochemical Targeting of Mitochondria for Breast Cancer Chemoprevention, Therapy, and Sensitization

  2022cites this paper
• Homoharringtonine inhibits melanoma cells proliferation in vitro and vivo by inducing DNA damage, apoptosis, and G2/M cell cycle arrest.

  2021cites this paper
• Update and New Insights on Future Cancer Drug Candidates From Plant-Based Alkaloids

  2021cites this paper
• Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay

  2021cites this paper
• Uncovering the action mechanism of homoharringtonine against colorectal cancer by using network pharmacology and experimental evaluation

  2021cites this paper
• Homoharringtonine Inhibits Alzheimer’s Disease Progression by Reducing Neuroinflammation via STAT3 Signaling in APP/PS1 Mice

  2021cites this paper
• Biodiversity, chemodiversity, and pharmacotherapy of Cephalotaxus medicinal plants

  2021cites this paper
• Inhibition of the Eukaryotic 80S Ribosome as a Potential Anticancer Therapy: A Structural Perspective

  2021cites this paper
• CRYβB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer

  2021cites this paper
• Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway

  2021influential citation
• Effect of Homoharringtonine on Proliferation and Apoptosis of Osteosarcoma Cells via LINC00857/miR-340

  2021cites this paper
• Medicinal Plants with Anti-Leukemic Effects: A Review

  2021cites this paper
• Ethnopharmacology, chemodiversity, and bioactivity of Cephalotaxus medicinal plants.

  2021cites this paper
• Homoharringtonine inhibited breast cancer cells growth via miR-18a-3p/AKT/mTOR signaling pathway

  2021cites this paper
• Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway

  2021cites this paper
• Targeting the Human 80S Ribosome in Cancer: From Structure to Function and Drug Design for Innovative Adjuvant Therapeutic Strategies

  2020cites this paper
• Revealing Chemopreventive Potential of Active Constituents from Medicinal Herbs Used in Indonesia for Breast Cancer with Particular Molecular Targets

  2020cites this paper
• Homoharringtonine Inhibits Allergic Inflammations by Regulating NF-κB-miR-183-5p-BTG1 Axis

  2020cites this paper
• Biodiversity, Chemodiversity, and Pharmacotherapy of Thalictrum Medicinal Plants

  2019cites this paper